Celltrion said on the 16th that its cancer drugs and autoimmune disease treatments are expanding both market share and prescriptions in major European countries.
The cancer drug "Vegzelma" (bevacizumab) has expanded supply by winning a series of major public tenders in France. Supply is being carried out through public hospital group purchasing organizations such as UniHA, HACOM, and GRAPS, and it has recorded a majority market share in the local bevacizumab market.
In the same market, "Herzuma" (trastuzumab) and "Truxima" (rituximab) are also continuing with tenders and supply. Celltrion is supplying all three cancer drugs in France.
In Germany, prescriptions are increasing based on a direct-sales system. Truxima and Vegzelma ranked first in prescriptions in the retail market, and Herzuma ranked second.
According to IQVIA, as of the fourth quarter of 2025, Vegzelma maintains the No. 1 position with about a 30% share in the European bevacizumab market.
The autoimmune disease treatment "Abtozma" (tocilizumab) was selected as a supplier in tenders for Spain's Basque and Madrid regions and in a tender by INGESA under the Ministry of Health. In Portugal, it secured the top-priority national tender supplier status for both the autoinjector and vial formulations.
In Germany, sales of Abtozma are increasing. For the subcutaneous (SC) formulation, first-quarter sales this year rose 57% from the previous quarter, and for the intravenous (IV) formulation, sales in February increased 87% from the previous month.
The expansion of Abtozma sales led to increased prescriptions of "Yuflyma" (adalimumab). Since Abtozma's launch, Yuflyma has continued to grow about 10% per quarter.
A Celltrion official said, "Based on the expansion of our product portfolio, tenders and prescriptions are expanding simultaneously in major European countries."